The International Testing Agency (ITA) has reported that a sample collected from boxer Cynthia Temitayo Ogunsemilore has returned an Adverse Analytical Finding for the prohibited substance Furosemide. Furosemide is classified as an S5 diuretic and masking agent on the World Anti-Doping Agency (WADA) Prohibited List.
The sample was collected by the ITA under the testing authority and results management authority of the International Olympic Committee (IOC) during an out-of-competition anti-doping control on July 25, 2024, in Paris, France. The WADA-accredited laboratory in Paris reported the result on July 27, 2024.
Ogunsemilore has been informed of the case and has been provisionally suspended pending the resolution of the matter in accordance with the World Anti-Doping Code and the IOC Anti-Doping Rules applicable to the Olympic Games Paris 2024. This suspension prevents her from competing, training, coaching, or participating in any Olympic Games-related activities during the ongoing event in Paris.
The athlete retains the right to challenge the provisional suspension before the Court of Arbitration for Sport – Anti-Doping Division (CAS ADD). Additionally, she can request the analysis of her B-sample.
The ITA, a not-for-profit organization dedicated to clean sport, manages the independent anti-doping program for the Olympic Games Paris 2024 on behalf of the IOC. The agency has stated that, given the ongoing nature of the case, no further comments will be made during the proceedings.
An Adverse Analytical Finding is a report from a WADA-accredited laboratory that establishes the presence of a prohibited substance, its metabolites, markers, or evidence of the use of a prohibited method in a sample, in accordance with the International Standard for Laboratories.
As the case progresses, the sports community and fans alike will await further developments regarding Ogunsemilore’s status and any potential implications for her career and participation in the Olympic Games.
